A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

PURPOSE: A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozkaynak, M. Fevzi, Gilman, Andrew L., London, Wendy B., Naranjo, Arlene, Diccianni, Mitchell B., Tenney, Sheena C., Smith, Malcolm, Messer, Karen S., Seeger, Robert, Reynolds, C. Patrick, Smith, L. Mary, Shulkin, Barry L., Parisi, Marguerite, Maris, John M., Park, Julie R., Sondel, Paul M., Yu, Alice L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016521/
https://www.ncbi.nlm.nih.gov/pubmed/29967609
http://dx.doi.org/10.3389/fimmu.2018.01355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016521/
https://www.ncbi.nlm.nih.gov/pubmed/29967609
http://dx.doi.org/10.3389/fimmu.2018.01355

Ejemplares similares